NHS Approves First New Ovarian Cancer Drug in 20 Years

The NHS announced on June 4 that mirvetuximab soravtansine (Elahere) is now available for hundreds of women with platinum-resistant ovarian cancer. This is the first genuinely new treatment option the NHS has added for ovarian cancer in more than two decades—a significant breakthrough for patients whose cancer has stopped responding to standard chemotherapy.

How the Drug Works

Mirvetuximab soravtansine is a monoclonal antibody, a type of protein designed to seek out and attack specific targets on cancer cells. This drug targets something called folate receptor-alpha (FRα), which appears on the surface of many ovarian cancer cells. Think of it like a guided missile: the antibody carries a toxic payload and delivers it directly to cells with this marker, minimizing damage to healthy tissue.

The drug was tested in a major trial called MIRASOL. Patients who received mirvetuximab soravtansine lived an average of 5.62 months before their cancer worsened, compared with 3.98 months for those on standard chemotherapy—a 35% reduction in the risk of disease progression or death. It works specifically for adults with ovarian, fallopian tube, or peritoneal cancer that is both folate receptor-alpha positive and resistant to platinum-based drugs.

The Approval Journey

Getting here was not straightforward. Britain's medicines regulator, the MHRA, had already approved the drug, but the NHS needed to make its own decision about whether to fund it. An independent organization called NICE, which evaluates whether new treatments offer good value for the NHS budget, initially said no—the evidence didn't show it was worth the cost.

That rejection was eventually reversed, likely because NHS England negotiated a different price arrangement with AbbVie, the drug's manufacturer. The exact financial terms remain confidential. This pattern has become increasingly common: when a treatment addresses a serious unmet need and standard cost-benefit calculations don't quite fit, the NHS and pharmaceutical companies work out a deal behind the scenes.

Why This Matters

Platinum-resistant ovarian cancer is a real problem. About one in four ovarian cancer patients develop resistance to platinum-based drugs—the previous standard treatment—at their first recurrence. Treatment options have barely changed in decades, leaving doctors and patients with limited alternatives. This drug fills that gap.

Antibody-drug conjugates—the platform this treatment uses—have proven successful in other cancers too. Similar drugs have worked well in breast cancer and other tumors, validating the approach of using antibodies as precision delivery vehicles. Folate receptor targeting in ovarian cancer was a logical next step.

The drug also received orphan medicine status from the European Medicines Agency in 2015, reflecting the small patient population and significant unmet need. That designation provides regulatory incentives for companies to develop treatments for rare diseases. The EU approved Elahere before the UK did, though individual European countries make their own reimbursement decisions.

What Comes Next for the NHS

NHS hospitals will need to set up some new systems to use this drug safely. First, patients must be tested to confirm their cancer actually has folate receptor-alpha—but this test isn't done routinely everywhere in Britain yet. The NHS may need to centralize testing or train more pathology labs to do it.

Second, cancer doctors and nurses will need training on how to administer the drug and manage its side effects, which differ from traditional chemotherapy. This means updating protocols and safety monitoring across NHS cancer centers.

The Bigger Picture

This approval says something about how the NHS is adapting in a tight budget environment. Rather than stick rigidly to cost-effectiveness thresholds, it's increasingly willing to find alternative paths—like commercial negotiations—to get innovative treatments to patients when the clinical need is clear and alternatives are scarce.

For pharmaceutical companies, the message is also clear: invest in antibody-drug conjugates and rare cancer treatments. The long regulatory timeline from NICE's initial rejection to final approval shows that persistence in reimbursement negotiations can pay off, especially for orphan indications where patients have few other options.

The traditional way the NHS evaluates new drugs—strict cost-effectiveness formulas applied to everyone equally—may need rethinking for rare cancers. When you have a small patient population and few good comparisons, those standard economic models don't always work well. The mirvetuximab soravtansine approval hints that the NHS is quietly evolving its approach, prioritizing patient access in specific therapeutic areas where the clinical case is strong enough.